ArticleOncogene2025

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.

Rocky Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.